Scholarlink

<p>This study aimed to develop an efficient <i>Saccharomyces cerevisiae</i>-based cell factory for heme production. The industrial strain <i>S. cerevisiae</i> KCCM 12638, a starter strain used in American whisky production, was selected for its naturally high heme concentration, and its medium composition was optimized. Next, CRISPR/Cas9-based genome editing was employed to enhance carbon flux through the heme biosynthetic pathway by overexpressing <i>HEM2</i>, <i>HEM3</i>, <i>HEM12</i>, and <i>HEM13</i> genes, which encode key enzymes involved in heme synthesis. Additionally, the <i>HMX1</i> gene, which encodes heme oxygenase 1, was inactivated to prevent heme degradation. The resulting ΔHMX1<i>_</i>H2/3/12/13 strain achieved a heme titer of 9 mg/L in batch fermentation, a 1.7-fold improvement over the wild-type KCCM 12638 strain. In a glucose-limited fed-batch fermentation, the ΔHMX1<i>_</i>H2/3/12/13 strain produced 67 mg/L heme. This study demonstrates that engineering industrial yeast strains can significantly enhance heme production, with promising applications in food, pharmaceuticals, and bioenergy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhanced heme production in industrial Saccharomyces cerevisiae through metabolic engineering

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月21日

查看全文
  • Hyun-Jae Lee,
  • Tae-Gi Lee,
  • Changhee Cho,
  • Gi-Beom Jeon,
  • Seongjin Oh,
  • Sun-Ki Kim

摘要

This study aimed to develop an efficient Saccharomyces cerevisiae-based cell factory for heme production. The industrial strain S. cerevisiae KCCM 12638, a starter strain used in American whisky production, was selected for its naturally high heme concentration, and its medium composition was optimized. Next, CRISPR/Cas9-based genome editing was employed to enhance carbon flux through the heme biosynthetic pathway by overexpressing HEM2, HEM3, HEM12, and HEM13 genes, which encode key enzymes involved in heme synthesis. Additionally, the HMX1 gene, which encodes heme oxygenase 1, was inactivated to prevent heme degradation. The resulting ΔHMX1_H2/3/12/13 strain achieved a heme titer of 9 mg/L in batch fermentation, a 1.7-fold improvement over the wild-type KCCM 12638 strain. In a glucose-limited fed-batch fermentation, the ΔHMX1_H2/3/12/13 strain produced 67 mg/L heme. This study demonstrates that engineering industrial yeast strains can significantly enhance heme production, with promising applications in food, pharmaceuticals, and bioenergy.